Ranjeet Ajmani To Speak at WHIF25
Ranjeet Ajmani, Chief Executive Officer- Asia at Aegros, reposted from World Health Innovation Forum on LinkedIn:
”Self-Reliance in Plasma Products: A Global Imperative
It is both an honor and a privilege to share my thoughts on how India can become self-reliant in the production of plasma-derived medicines (PDMPs), and how this can help many other developing countries improve their plasma collection, regulatory frameworks, and public health policies.
By collaborating on these areas, we can enable countries to either pursue contract fractionation or even set up their own fractionation plants, ensuring they meet the urgent healthcare needs of their populations.
Considering the current geopolitical landscape, this initiative is more critical than ever.
Self-sufficiency in plasma products not only strengthens national healthcare systems but also reduces dependence on international suppliers, mitigating risks tied to global supply chain disruptions.
Now is the time for sharing knowledge, expertise, and learning for the greater good.
After all, patients are patients, and their right to safe, accessible PDMPs should never be questioned.
Together, we can build a future where no one is left behind in the pursuit of better healthcare.”
Quoting World Health Innovation Forum‘s post:
”The visionary shaping Asia’s plasma biopharma landscape!
We are honoured to welcome Dr. Ranjeet Ajmani, Chief Executive Officer – Asia at Aegros, as a speaker at the World Health Innovation Forum (WHIF) 2025.
A pioneer in plasma-derived biopharmaceuticals, Dr. Ajmani has redefined India’s plasma industry, from conceptualizing and executing India’s first contract plasma fractionation model to successfully converting over 100,000 liters of human plasma into Albumin, IVIG, and Factor VIII at highly competitive prices.
His leadership blends strategic vision, operational excellence, and an unwavering commitment to ethical, transparent, and accountable organizational culture.
Join us at WHIF25, hosted by Andhra Pradesh MedTech Zone Limited, to hear from leaders like Dr. Ajmani who are driving innovation, ensuring equitable access, and setting new benchmarks in global healthcare.
December 11–13, 2025
Register now.”
Stay updated with Hemostasis Today.
-
Apr 8, 2026, 18:14Simon Fletcher: See The Unique Challenges PwH Face During Their Gene Therapy Journey
-
Apr 8, 2026, 17:56Hisam Siddiqi: Understanding Bone Marrow Trephine Morphology in MPNs
-
Apr 8, 2026, 17:46Mohamed Reda: Why Some Veins Decide to Take a ‘Detour’?
-
Apr 8, 2026, 17:39Managing Acquired Von Willebrand Syndrome in a Swine Polytrauma Model During ECLS – JTH
-
Apr 8, 2026, 17:04Heghine Khachatryan: Marfan vs LDS – Not All Aortopathies Are the Same
-
Apr 8, 2026, 17:00Frits Rosendaal Receives ISTH Grant Medal for Lifetime Contributions to Thrombosis and Hemostasis Field
-
Apr 8, 2026, 16:25Xiaoying Chen: Teleneurological Ward As A Practical Way to Support High-Quality Stroke Care Beyond Major Centres
-
Apr 8, 2026, 16:24Ney Carter Borges: Endocrine Drivers of Resistant Hypertension – Insights from the MOMENTUM Trial at ACC 26
-
Apr 8, 2026, 16:21Jonathan Gelber: Exploring Papaya Extract as an Option to Elevate Platelet Numbers Before PRP